Abstract

There is controversy concerning whether radiofrequency ablation (RFA) or surgical resection (SR) is a better treatment option for recurrent HCC after resection. In Kaohsiung Veteran General Hospital, from January 2002 to September 2014, a total of 100 consecutive patients who developed recurrent HCCs with a tumor size ≦ 3 cm and tumor numbers ≦ 3 after surgical resection were enrolled. Among these patients, 57 patients received RFA and 43 patients underwent repeated SR. Baseline characteristics at the time of recurrence after hepatic resection and clinical outcomes following treatment of recurrent HCC were compared between the two groups. The baseline data of initial HCC and the first recurrence of HCC were comparable in both groups. The 1-, 3-, 5-year overall survival rates following treatment of the first recurrence of HCC were 97.6%, 82.7%, 56.4% in the repeated SR group and 98.2%, 77.2%, 52.6% in the RFA group (p = 0.69). The 1-, 3-, 5-year disease-free survival rates were 57.0%, 32.1%, 28.6% in the repeated SR group and 60.8%, 26.6%, 16.6% in the RFA group ((p = 0.89). There was a trend whereby patients who underwent repeated SR had more procedure-related morbidity than patients who underwent RFA (16% vs. 7%, p = 0.14). The median total hospital days were longer in the repeated SR group than that in the RFA group (13 vs. 5 days, p < 0.05). In the small recurrent HCCs after SR, RFA achieved similar overall survival and disease-free survival than those with repeated SR as well as having a shorter hospital stay.

Highlights

  • The curative treatment modalities for hepatocellular carcinoma (HCC) include liver transplantation, surgical resection (SR), and radiofrequency ablation (RFA)

  • Repeated SR for recurrent HCC has been reported to be an effective treatment option with a comparable survival rate to that of primary SR [16,17,18], but its feasibility is limited by small liver remnants, poor liver function reserve, or technical difficulties owing to expected postoperative adhesion [19,20,21]

  • Many of the studies were limited by small case numbers or large tumor size [25,26,27,28,29,30,31] and there remain many controversies regarding the choice of repeated SR and RFA in treating recurrent tumor after primary resection

Read more

Summary

Introduction

The curative treatment modalities for hepatocellular carcinoma (HCC) include liver transplantation, surgical resection (SR), and radiofrequency ablation (RFA). Liver transplantation is the best treatment option for patients with HCC, SR and RFA are most commonly considered first-line treatments because of the graft shortage. Numerous studies suggest both SR and RFA are comparable in terms of long-term survival for patients with early stage HCC. Repeated SR for recurrent HCC has been reported to be an effective treatment option with a comparable survival rate to that of primary SR [16,17,18], but its feasibility is limited by small liver remnants, poor liver function reserve, or technical difficulties owing to expected postoperative adhesion [19,20,21]. This study aimed to compare the efficacy, safety, and long-term survival of repeated SR and RFA for recurrent HCCs

Objectives
Methods
Conclusion
Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call